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Abstract
Background: Iophenoxic acid is an iodinated radiocontrast agent that was withdrawn from clinical use because of
its exceptionally long half-life in the body, which was due in part to its high-affinity binding to human serum
albumin (HSA). It was replaced by Iopanoic acid, which has an amino rather than a hydroxyl group at position 3
on the iodinated benzyl ring and, as a result, binds to albumin with lower affinity and is excreted more rapidly
from the body. To understand how iophenoxic acid binds so tightly to albumin, we wanted to examine the
structural basis of its interaction with HSA.
Results: We have determined the co-crystal structure of HSA in complex with iophenoxic acid at 2.75 Å resolution,
revealing a total of four binding sites, two of which – in drugs sites 1 and 2 on the protein – are likely to be
occupied at clinical doses. High-affinity binding of iophenoxic acid occurs at drug site 1. The structure reveals that
polar and apolar groups on the compound are involved in its interactions with drug site 1. In particular, the 3-
hydroxyl group makes three hydrogen bonds with the side-chains of Tyr 150 and Arg 257. The mode of binding to
drug site 2 is similar except for the absence of a binding partner for the hydroxyl group on the benzyl ring of the
compound.
Conclusions: The HSA-iophenoxic acid structure indicates that high-affinity binding to drug site 1 is likely to be
due to extensive desolvation of the compound, coupled with the ability of the binding pocket to provide a full set
of salt-bridging or hydrogen bonding partners for its polar groups. Consistent with this interpretation, the structure
also suggests that the lower-affinity binding of iopanoic acid arises because replacement of the 3-hydroxyl by an
amino group eliminates hydrogen bonding to Arg 257. This finding underscores the importance of polar
interactions in high-affinity binding to albumin.
Background
Iophenoxic acid (Teridax; 2-[(3-hydroxy-2,4,6-triiodo-
phenyl)methyl]butanoic acid) was introduced in the
mid-1950s as an oral radio-contrast agent for cholecys-
tography, a diagnostic procedure that relies on X-ray
imaging of the gallbladder. This small-molecule com-
pound, which contains three electron-dense iodine
atoms, was effective for this purpose because it accumu-
lated rapidly in the gallbladder. But iophenoxic acid was
withdrawn from clinical use in 1957 after being found
to have an astoundingly long half-life in the human
body, estimated to be at least two and a half years [1,2].
The long residency of iophenoxic acid was thought
likely to perturb both thyroid function and tests of thyr-
oid activity that relied on measurement of the plasma
concentration of the iodine-containing hormones that it
secretes [3]. The compound was largely replaced by the
closely related molecule, iopanoic acid. Intriguingly,
although iopanoic acid only differs from iophenoxic acid
by the substitution of an OH group by NH2 in the triio-
dophenyl ring (Figure 1), it has a much shorter half-life
(~2 weeks) [4]. The striking difference in persistence of
these two radio-contrast agents is attributed at least in
part to their interactions with human serum albumin
(HSA) [5].
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plasma and tissue fluids, typically around 0.6 mM and
can have a profound effect on the distribution of many
natural and artificial small-molecules [2]. The protein
circulates as a monomeric polypeptide that folds into
three similar helical domains (I-III), each of which is
split into two sub-domains (A and B) [6] (Figure 2b).
Between them these six sub-domains provide binding
sites for a wide variety of endogenous ligands that are
predominantly apolar molecules with anionic or electro-
negative features and include fatty acids, bilirubin,
hemin and thyroxine [2,7]. Two of the binding pockets
on the protein have been identified as the primary sites
for drugs and drug-like compounds [8,9]. Crystallo-
graphic analysis has shown that these pockets – drug
sites 1 and 2 – are located in sub-domains IIA and IIIA
respectively [10,11], although additional drug binding
sites have also been found [10,12-14].
Iophenoxic acid is one of the tightest binding artificial
ligands of HSA (Kd ~ 20 nM) [2,4,15]. A high affinity
for albumin is an important contributory factor to its
persistence in blood plasma since this severely limits the
free concentration of the compound, which, for reasons
that are still not well understood, exerts an unusually
powerful restriction on the rate of excretion of the com-
pound [3].
Competition binding experiments showed that iophe-
noxic acid most readily displaces compounds that are spe-
cific for drug site 1 (e.g. warfarin) and strongly suggest its
primary binding site is within sub-domain IIA [9,16]. The
compound also competes, though less effectively, with
drugs that are specific for drug site 2 (e.g. diazepam) [17],
indicating weaker binding to this site [4]. In contrast, the
structurally-related iopanoic acid (Figure 1) binds to HSA
with much lower affinity (Kd ~ 150 nM) [19,20] and
appears to bind preferentially to drug site 2, since it is most
readily displaced by dansylsarcosine [8] and diazepam [15].
Though no longer administered to humans, the excep-
tional retention time of iophenoxic acid has led to it
being used as a marker for tracking a variety of wild
mammals including raccoons[ 1 8 ] ,b a d g e r s[ 1 9 ] ,s w i n e
[20] and Arctic foxes [21]. The compound presumably
also binds to the albumins found in the plasma of these
creatures. In addition, related compounds including
iopanoic acid are being studied as possible treatments
for hyperthyroidism [22].
We were therefore curious to understand how iophe-
noxic acid binds to drug site 1 on HSA with a high
Iophenoxic Acid Iopanoic Acid
Figure 1 Chemical structures of iophenoxic acid and iopanoic
acid.
Figure 2 Co-crystal structure of HSA in complex with iophenoxic acid. (a) Simulated annealing omit map contoured at 3s for iophenoxic
acid bound in drug site 1 in sub-domain IIA. (b) Overview of HSA, coloured by sub-domain, showing the locations of the two primary drug sites
and the four molecules of iophenoxic acid. (c) Close-up of iophenoxic acid bound in drug site 1. The ligand and selected side-chains are shown
as sticks, coloured by atom type (carbon - grey (yellow in the iophenoxic acid); oxygen - red; nitrogen - blue; iodine - magenta). The surface of
iophenoxic acid is shown as a semi-transparent grey surface. Hydrogen bonds and salt bridges are indicated by dotted orange lines.
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structural similarity. To that end we attempted to deter-
mine the crystal structure of defatted HSA in complex
acid with both compounds. Although HSA-iopanoic
acid co-crystals failed to grow, we succeeded in deter-
mining the crystal structure of HSA-iophenoxic acid
and this provides a clear explanation for the disparate
binding affinities of the two iodinated compounds.
Results and Discussion
HSA-iophenoxic acid complexes crystallised isomor-
phously with defatted HSA in a P1 space-group that
contains two molecules in the asymmetric unit. The
crystal structure was solved by molecular replacement at
a resolution of 2.75 Å and strong electron density was
observed for iophenoxic acid binding in drug sites 1 and
2 (Figure 2a, b). In these sites the iodine atoms could be
positioned accurately by contouring the electron density
m a pa t6 s;a t3 s density for the 2-ethyl-propanoate
group became evident, allowing an unambiguous deter-
mination of the orientation of the ligand in each case.
Weaker density for the iodine atoms of iophenoxic
acid was observed (at 1.5-2.5s) in two additional binding
s i t e s ,o n ew i t h i ns u b - d o m a i nI Ba n do n ei nas h a l l o w
cleft between sub-domains IIIA and IIIB (Figure 2b).
However, for both these sites, although the electron
density for the iodine atoms clearly establishes the bind-
ing location, it does not give an indication of the other
features of the ligand molecule. Consequently, these
iophenoxic acid molecules have been built into the
model in indicative orientations that avoid steric clashes
and are consistent with the local physicochemistry.
The model was refined to yield a final Rfree value of
23.9% (Materials and Methods). Full data collection and
refinement statistics are given in Table 1.
Drug site 1
Iophenoxic acid fits snugly into the main chamber of
drug site 1 where, with the exception of the carboxylate
group, it is entirely shielded from solvent (Figure 2c). As
observed for many other aromatic compounds [10,23],
the centre of the tri-iodinated ring is contacted on
either side by the side-chains of Leu 238 and Ala 291
(Figure 3a). In particular, it is worth noting that the
radiocontrast agent binds is a similar position and orien-
tation to other compounds that are composed primarily
of iodinated aromatic rings, such as tri-iodobenzoic acid,
di-iodosalicylic acid and iodipamide [10,24] (Figure 3b);
for all three compounds there is a common locus for at
least two iodine atoms (three in the case of iodipamide).
The bound conformation allows all the polar features
of iophenoxic acid to make specific interactions with
polar side-chains of residues lining the pocket in sub-
domain IIA. The hydroxyl group on the aromatic ring
makes a total of three hydrogen bonds with Tyr 150
and Arg 257; the position of these amino acids in rela-
tion to iophenoxic acid suggests the ligand hydroxyl
donates a single bond to the OH group on Tyr 150 and,
accepts two from the guanidinium group of Arg 257 (all
2.7-2.9 Å) (Figure 2c). At the other end of the molecule,
the side-chains of Lys 199 and Arg 222 on opposite
sides of the pocket entrance make salt-bridges to the
carboxylate group on iophenoxic acid.
Our structure is consistent with results from competi-
tion binding experiments that identified drug site 1 as
the primary high-affinity binding site for iophenoxic
acid [9,16]. The near complete desolvation of the com-
pound in the pocket and the comprehensive matching
of polar groups provide a plausible account for the high
affinity of iophenoxic acid for this binding site.
Drug site 2
There are many similarities in the binding of iophenoxic
acid to drug sites 1 and 2. In drug site 2 the compound
is completely enclosed except for the partial exposure of
the carboxylate at the pocket entrance, where it makes
specific interactions – though in this case they are
hydrogen bonds, not salt-bridges – with the side-chains
Table 1 Data collection and refinement statistics
Space-group P1
a, b, c (Å) 55.07, 55.44, 119.85
a, b, g (°) 81.00, 90.83, 64.52
Resolution range (Å) 59-2.75
Independent reflections 31655
Multiplicity
1 1.9 (1.9)
Completeness (%) 95.5 (92.9)
I/s
I 8.2 (1.7)
Rmerge (%)
2 9.1 (34.5)
MODEL REFINEMENT
Nonhydrogen atoms
Rmodel (%)
3 19.6
Rfree (%)
4 23.2
r.m.s bonds (Å) 0.009
r.m.s bond angles (°) 1.18
Average overall B-factor (Å
2) 46.2
Average ligand B-factors (Å
2)
5 18.0, 36.2, 87.1, 111.9
Ramachandran plot (% favoured/allowed) 89.9/8.4
PDB ID 2ydf
1Values for the outermost resolution shell are given in parentheses.
2Rmerge = 100 × ΣhΣj|Ihj -I h|/ΣhΣjIhj where Ih is the weighted mean intensity of
the symmetry related reflections Ihj
3Rmodel = 100 × Σhkl|Fobs -F calc|/ΣhklFobs where Fobs and Fcalc are the observed
and calculated structure factors respectively.
4Rfree is the Rmodel calculated using a randomly selected 5% sample of
reflection data omitted from the refinement.
5Average B-factors given for iophenoxic acid ligands bound to sub-domains
IIA, IIIA, IB and in the IIIA-IIIB sites respectively.
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is again positioned deep within the pocket but, although
it is in the vicinity of the backbone carbonyl of Leu 430
[10], it is too far away (4.4 Å) to make a hydrogen bond
interaction. In contrast to the smaller propofol molecule
(see Figure 2 of ref [25]), the steric hindrance caused by
the three bulky iodine atoms prevents iophenoxic acid
from rotating to a position that would allow the hydro-
xyl group to form a hydrogen bond with this group.
Two of the iodine atoms of iophenoxic acid in drug
site 2 are accommodated within the main chamber,
while the third inserts partially into a sub-chamber that
was first observed in the structure of the HSA-diazepam
structure (Figure 4b). The sub-chamber is accessed as a
result of displacement of the side-chains of Leu 387 and
Leu 453 by the phenyl group of diazepam [10]; however,
in the case of iophenoxic acid the conformational altera-
tion is more modest – only the side-chain of Leu-387
has to be rotated to accommodate one of the iodine
atoms of the compound (Figure 4b).
It therefore appears that a combination of factors –
absence of a hydrogen bonding partner for the hydroxyl
group, substitution of hydrogen bonds for salt-bridges
interacting with the carboxylate group and perhaps also
the induced conformation change in Leu 387 - contri-
bute to the lower affinity of iophenoxic acid for drug
site 2 in comparison with drug site 1 [4,17].
Other binding sites
Because of the markedly reduced strength of the elec-
tron density for the third and fourth sites, it seems likely
that these are only occupied as a result of the high con-
centrations of iophenoxic acid used to prepare co-crys-
tals and unlikely that they are physiologically relevant
binding sites. Moreover, since the orientation of the
compounds cannot be unambiguously assigned, it is dif-
ficult to provide detailed information on the mode of
binding. However, the orientation of the tri-iodinated
ring is clearly discerned and it is worth noting that
iophenoxic acid binds to a site in sub-domain IB that
w a sp r e v i o u s l yo b s e r v e dt ob eas e c o n d a r yb i n d i n gs i t e
for indomethacin, a drug that also binds primarily to
drug site 1. This location overlaps with the outer part of
the observed common binding site of 4Z,1 5 E-bilirubin-
IXa and fusidic acid [13], an observation that may
explain why iophenoxic acid can displace bilirubin from
HSA [15,26].
The fourth iophenoxic molecule binds to a shallow
surface cleft between sub-domains IIIA and IIIB, and
partially overlaps a site that was observed to be a site of
secondary binding for the drug oxyphenbutazone in the
ternary HSA-myristate-oxyphenbutazone complex [10].
The difference between Iophenoxic and Iopanoic acid
binding
Although we were unable to obtain diffraction-quality
co-crystals of HSA in complex with iopanoic acid, the
structure of the HSA-iophenoxic acid complex pro-
vides a plausible explanation for the difference in bind-
ing behavior of these very similar iodinated
compounds, particularly with regard to drug site 1.
Iophenoxic acid binds with high affinity (Kd ~2 0n M )
to this site because it is a good fit to the dimensions
of the pocket and makes specific interactions with its
polar groups (Figure 2c). In particular its hydroxyl
group can form three hydrogen bonds with Tyr 150
and Arg 257 deep within the pocket. The replacement
of this hydroxyl group with an NH2 group in iopanoic
Figure 3 Comparative binding of iophenoxic acid and other ligands to drug site 1 of HSA. (a) Superposition of iophenoxic acid and
warfarin [23]. Y150 is omitted from this figure to improve the visibility of the ligands. (b) Superposition of iophenoxic and other iodinated
compounds that bind to drug site 1, including iodipamide (iod), tri-iodobenzoic acid (tib), di-iodosalicylic acid (dis) and thyroxine (trx) [10,24,30].
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pound is likely to bind in the same orientation as
observed for iophenoxic acid. This assumption is sup-
ported by drug site 1 modeling experiments performed
with the docking software, GOLD, which found that
seven of the highest-scoring solutions docked iopanoic
acid in the pocket in an orientation very similar to
iophenoxic acid and placed the NH2 group close to the
side-chains of Tyr 150 and Arg 257. However, the
NH2 group in iopanoic acid has less hydrogen binding
capability in this position than the hydroxyl group in
iophenoxic acid. The low pKa value of an NH2 substi-
tuent on an aromatic ring means that it is likely only
to be able to donate hydrogen bonds, so the com-
pound would only be able to make a single hydrogen
bond, with Tyr 150.
The observed mode of interaction of iophenoxic acid
with drug site 1 on HSA is reminiscent of a similar find-
ing for CMPF (3-carboxy-4-methyl-5-propyl-2-furanpro-
panoic acid), a more polar compound which
nevertheless also binds to this site with good affinity (Kd
= 100 nM) [27] as a result of specific interactions invol-
ving all the polar groups on the ligand [10]. Thus it
appears that ligands with significant polar features can
bind to HSA with high affinity if their hydrophilic
groups can all find specific interacting partners within
the binding site.
As well as reducing its binding affinity for site 1, this
structural difference in iopanoic acid also appears to
confer a preference for drug site 2 in sub-domain IIIA,
though its selectivity for this binding pocket is less
marked than the site 1/site 2 selectivity of iophenoxic
acid [28]. Given the close structural similarity between
the two compounds, it seems likely that iopanoic acid
could bind to drug site 2 in precisely the same orienta-
tion as observed for iophenoxic acid. In this case, the
NH2 group would still be too far from the carbonyl
group of Leu 430 (or any other nearby carbonyl) to
make a hydrogen bond. While this may account for its
lower affinity (KD ~ 150 nM) for the protein [4], it
remains a puzzle why iopanoic acid preferentially binds
to drug site 2, especially since the NH2 group would be
predicted to hydrogen bond to Tyr 150 in drug site 1.
The factors governing the differential binding of this
compound to drug sites 1 and 2 on albumin are evi-
dently quite complex.
Conclusions
The crystal structure of the HSA-iophenoxic acid com-
plex reveals a total of four binding sites on the protein,
only two of which are likely to be physiologically rele-
vant. It indicates that high-affinity binding to drug site 1
is likely to be due to extensive desolvation of the com-
pound, coupled with the ability of the binding pocket to
provide a full set of salt-bridging or hydrogen bonding
partners for its polar groups.
Recognition of the hydroxyl group on the iodinated
benzyl ring by the side-chains of Tyr 150 and Arg 257
appears to be particularly crucial to binding. The repla-
cement of this hydroxyl by an amino group in iopanoic
acid is predicted to lower the binding affinity by redu-
cing the number of hydrogen bonds made with Tyr 150
and Arg 257.
Figure 4 Structural details of iophenoxic acid bound to drug
site 2 in sub-domain IIIA. (a) Close-up of iophenoxic acid bound
in drug site 2, using the same representation of features as in
Figure 2c). (b) Superposition of iophenoxic acid and diazepam (dzp)
[10]. The side-chain conformations of L387 and L453 in the HSA-
diazepam complex are shown as dark-grey sticks.
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Recombinant HSA was kindly donated by Prof. Eishun
Tsuchida (Waseda University, Japan) and was defatted
and purified in preparation for crystallisation as described
previously [10]. Iophenoxic acid was obtained from
Sigma Aldrich at the highest available purity and was
solubilised in dimethylsulphoxide (DMSO). HSA-iophe-
noxic acid complexes were prepared using established
methods [10]: HSA at 100 mg/ml in 50 mM potassium
phosphate, pH7 was mixed with sufficient 100 mM
iophenoxic acid in DMSO to achieve a 5:1 molar ratio of
the compound to the protein. This mixture was incu-
bated with rotation at room temperature for an hour and
the excess, unbound iophenoxic acid was removed by
repeated cycles of dilution with 50 mM potassium phos-
phate, pH7 containing 20 μM iophenoxic acid in a 10 kD
MW cut-off centrifugal ultra-filtration device. The com-
plex was crystallised at 100 mg/ml from 24-30% (w/v)
polyethylene glycol 3350 as reported [10,25].
X-ray diffraction data were collected at room tempera-
ture from capillary-mounted crystals on beamline 14.1
at SRS Daresbury, using methods established in our
laboratory for HSA crystals [7]. Data processing and
scaling were performed using MOSFLM and SCALA
from the CCP4 suite [29]. The crystals grew isomor-
phously to the P1 crystals previously obtained for
defatted HSA [10,25,30] and the data were phased by
molecular replacement using a previously determined
high-resolution structure of defatted HSA (PDB 2bxa)
stripped of its ligands [10]. Rounds of model building in
O [31] were interleaved with cycles of refinement with
CNS [32]. The structure of iophenoxic acid used in
model building was obtained from the Cambridge Struc-
tural Database via the Chemical Database Service [33].
Final rounds of refinement, which included translation,
libration and screw-rotation (TLS) refinement using
groups defined by the TLS Motion Determination web-
server [34] were performed with Phenix [35].
For docking experiments, structures of iophenoxic
acid and iopanoic acid were generated in ChemBio3D
12.0 (CambridgeSoft, 2009) the structures then under-
went energy minimisation in Avogadro http://avogadro.
openmolecules.net/. Docking was carried out into the
structure of HSA (PDB: 2BXA[10]) stripped of all of its
ligands. Docking of iophenoxic acid and iopanoic acid
into HSA was carried out using GOLD 5.0.1 [36]. Dock-
ing solutions were obtained for positions within a radius
of 20 Å of the hydroxyl of Tyr 150. All amino acid side
chains were set as rigid during the docking while the
ligand was allowed to be flexible.
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